Tone mix
Week by week 52 weeks
Share of Mineralys Therapeutics, Inc. Common Stock's 141 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Feb 2, 2026 · tone +100Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones+86
- Week of Jan 26, 2026 · tone +100Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones+86
- Week of Oct 6, 2025 · tone +100Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring A 15% Potential Upside In The Biotech Sector+64
- Week of Dec 8, 2025 · tone +100Mineralys Therapeutics (MLYS): Investor Outlook Reveals Nearly 30% Upside Potential+62
- Week of Dec 15, 2025 · tone +94Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association "Research of the Year" Roundup+49
- Week of Jul 6, 2026 · tone +50A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger+48
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Mineralys Therapeutics, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 2 | +49 |
| Last 30 sessions | 14 | +14 |
| Last 90 sessions | 32 | +9 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Wednesday, October 28, 2026
1 headline, average tone +99: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletMineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney InternationalPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International | www.manilatimes.net | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletMineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026 | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 20, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletMineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel CoatsNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 15, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletMineralys Therapeutics (NASDAQ:MLYS) Upgraded at UBS GroupPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Mineralys Therapeutics (NASDAQ:MLYS) Upgraded at UBS Group | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 12, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletMineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Mineralys Therapeutics, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.